Search

Your search keyword '"Matoba, Yusuke"' showing total 11 results
Start Over Author "Matoba, Yusuke" Publication Year Range Last 3 years
11 results on '"Matoba, Yusuke"'

1. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma

Author

Matoba, Yusuke, Zarrella, Dominique T., Pooladanda, Venkatesh, Azimi Mohammadabadi, Maryam, Kim, Eugene, Kumar, Shaan, Xu, Mengyao, Qin, Xingping, Ray, Lauren J, Devins, Kyle M., Kumar, Raj, Kononenko, Artem, Eisenhauer, Eric, Veillard, Irva E., Yamagami, Wataru, Hill, Sarah J., Sarosiek, Kristopher A., Yeku, Oladapo O., Spriggs, David R., and Rueda, Bo R.

Published
2024
Full Text
View/download PDF

3. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells

Author

Linder, Samantha J., Bernasocchi, Tiziano, Martínez-Pastor, Bárbara, Sullivan, Kelly D., Galbraith, Matthew D., Lewis, Caroline A., Ferrer, Christina M., Boon, Ruben, Silveira, Giorgia G., Cho, Hyo Min, Vidoudez, Charles, Shroff, Stuti, Oliveira-Costa, Joao P., Ross, Kenneth N., Massri, Rami, Matoba, Yusuke, Kim, Eugene, Rueda, Bo R., Stott, Shannon L., Gottlieb, Eyal, Espinosa, Joaquin M., and Mostoslavsky, Raul

Published
2023
Full Text
View/download PDF

4. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway

Author

Zhang, Junbing, Simpson, Claire M., Berner, Jacqueline, Chong, Harrison B., Fang, Jiafeng, Ordulu, Zehra, Weiss-Sadan, Tommy, Possemato, Anthony P., Harry, Stefan, Takahashi, Mariko, Yang, Tzu-yi, Richter, Marianne, Patel, Himani, Smith, Abby E., Carlin, Alexander D., Hubertus de Groot, Adriaan F., Wolf, Konstantin, Shi, Lei, Wei, Ting-Yu, Dürr, Benedikt R., Chen, Nicholas J., Vornbäumen, Tristan, Wichmann, Nina O., Mahamdeh, Mohammed S., Pooladanda, Venkatesh, Matoba, Yusuke, Kumar, Shaan, Kim, Eugene, Bouberhan, Sara, Oliva, Esther, Rueda, Bo R., Soberman, Roy J., Bardeesy, Nabeel, Liau, Brian B., Lawrence, Michael, Stokes, Matt P., Beausoleil, Sean A., and Bar-Peled, Liron

Published
2023
Full Text
View/download PDF

5. Abstract A113: Extracellular vesicles derived from enriched ovarian cancer stem cell fractions promote stem like properties in the more vulnerable tumor cell populations

Author

Pooladanda, Venkatesh, primary, Kumar, Shaan, additional, Matoba, Yusuke, additional, Mohammadabadi, Maryam Azimi, additional, Zarrella, Dominique T., additional, Winter, Ursula A., additional, Hill, Sarah J., additional, Im, Hyungsoon, additional, and Rueda, Bo R., additional

Published
2024
Full Text
View/download PDF

6. Abstract 2438: Loss of galectin 3 reveals its potential roles in the aggressive pathology of uterine serous carcinoma

Author

Matoba, Yusuke, primary, Zarrella, Dominique T., additional, Pooladanda, Venkatesh, additional, Kim, Eugene, additional, Kumar, Shaan, additional, Xu, Mengyao, additional, Qin, Xingping, additional, Kumar, Raj, additional, Kononenko, Artem, additional, Veillard, Irva, additional, Sarosiek, Kristopher, additional, Yeku, Oladapo, additional, Spriggs, David R., additional, and Rueda, Bo R., additional

Published
2023
Full Text
View/download PDF

10. The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer.

Author

Bouberhan S, Bar-Peled L, Matoba Y, Mazina V, Philp L, and Rueda BR

Abstract

Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or short-lived. Over the last several years, multiple new classes of agents targeting DNA damage response (DDR) mechanisms have advanced through clinical development. In this review, we explore the preclinical rationale for the use of ATR inhibitors, CHK1 inhibitors, and WEE1 inhibitors, emphasizing their application to chemotherapy-resistant and PARPi-resistant ovarian cancer. We also present an overview of the clinical development of the leading drugs in each of these classes, emphasizing the rationale for monotherapy and combination therapy approaches., Competing Interests: All authors declared that there are no conflicts of interest., (© The Author(s) 2023.)

Published
2023
Full Text
View/download PDF

11. Keio Uterus Transplantation Research: From Basic Research toward Future Clinical Application.

Author

Kisu I, Banno K, Matoba Y, Yamada Y, Emoto K, Masugi Y, Matsubara K, Obara H, and Aoki D

Subjects
Animals, Female, Forecasting, Humans, Primates, Research, Uterus transplantation, Infertility, Female therapy
Abstract

Uterus transplantation (UTx) is now a potential option to allow women with uterine factor infertility to give birth. However, UTx is still at an experimental stage, and basic animal studies, including in non-human primates, are needed for the accumulation of data prior to clinical application. Considering that UTx may provide new hope to Japanese women, we launched UTx research in 2009 and have since accumulated a large archive of results in the UTx research field. Furthermore, we have carried out various activities aimed at the implementation of clinical applications of UTx in Japan while clarifying the ethical and social issues involved. Currently, the clinical application of UTx in Japan is just around the corner, and it is expected that UTx research will develop further in the future. Herein, we summarize our basic experiences using non-human primates and our activities with the goal of future clinical applications.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results